CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Nevada is a non-invasive urine test developed to identify men at risk of prostate cancer, aiming to reduce unnecessary biopsies. The test will be converted into a Point of Care assay, improving patient care and reducing healthcare costs across Europe.
Prostate cancer (PCa) is one of the most common types of cancers.
As an age-related disease, it is very infrequent below the age of 40 but very common above 65.
Currently in Europe, 1 in 7 men will develop PCa before reaching age of 85.
With population growth and ageing, the numbers of PCa diagnoses and PCa deaths are likely to substantially increase.
It is estimated that by 2030, with an increase in the proportion of people over 65, the number of PCa cases will quadruple.
Most PCa’s are first f…
MDXHEALTH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
